目的：长效阿片受体激动剂美沙酮对阿片依赖的有效治疗提示，慢启动长效多巴胺受体(DAT)抑制剂很可能对精神兴奋剂成瘾具有潜在治疗作用。

    方法：为验证此假设，我们成功地研制出慢启动长效DAT抑制剂CTDP32-476，并进一步研究其在成瘾性动物模型中的治疗作用。

    结果：(1)腹腔注射(ip)CTDP32，476(10-20 mg·kg-1)可缓慢但长时间增高伏隔核内细胞外多巴胺浓度；(2)无药物史的老鼠不能自身给药CTDP32-476，但能自身给药可卡因；(3)将可卡因自身给药的老鼠转换为CTDP32-476自身给药后，自身给药行为表现为低频率、不规则、并随时间进行性降低；(4) 与相同剂量的可卡因相比，CTDP32-476在累进比(progressive-ratio) 的自身给药模式下，为获得药物的断点(break-point) 明显较低；(5)将可卡因自身给药的老鼠给予CTDP32-476前处理后，CTDP32-476产生了剂量依赖性、长时间(-24 h)地抑制可卡因自身给药行为。

    结论：研究提示，(1)慢启动长效DAT抑制剂CTDP32-476的成瘾性低于可卡因；(2) CTDP32-476对可卡因或其他精神兴奋剂的成瘾性有潜在治疗作用。

　　参考文献：

　　[1] Lewis DB，Matecka D，Zhang Y，et al.Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]-and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents[J].J Med Chem，1999，42：5029-5042.

　　[2] Howell LL，Wilcox KM.The dopamine transporter and cocaine medication development：drug self-administration in nonhuman primates[J].J Pharmacol Exp Ther，2001，298：1-6.

　　[3] Gardner EL，Liu X，Paredes W，et al.A slow-onset，long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse：Effects in laboratory rat models relating to addiction[J].Neuropharmacology，2006，51：993-1003.

　　[4] Wolraich ML，Doffing MA.Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate[J].CNS Drugs，2004，18：243-250.

　　[5] Patrick KS，Straughn AB，Perkins JS，et al.Evolution of stimulants to treat ADHD：transdermal methylphenidate[J].Hum Psychopharmacol，2009，24：1-17.

　　[6] Wise RA，Gardner EL.Animal models of addiction[M]//Charney DS，Nestler EJ，eds.Neurobiology of mental illness (second edion).London：Oxford University Press，2004，683-697.

　　[7] Xi ZX，Gilbert JG，Pak AC，et al.Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats[J].Eur J Neurosci，2005，21：3427-3438.

　　[8] Paxinos G，Watson C.The rat brain in stereotaxic coordinates[M].4th edition.Sydney：Academic Press，1998.

　　[9] Xi ZX，Ramamoorthy S，Shen H，et al.GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine[J].J Neurosci，2003，23：3498-3505.

　　[10] Froimowitz M，Wu KM，Moussa A，et al.Slow-onset，long-duration 3-(3'，4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse[J].J Med Chem，2000，43：4981-4992.

　　[11] Froimowitz M，Gu Y，Dakin LA，et al.Slow-onset，long-duration，alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter[J].J Med Chem，2007，50：219-232.

　　[12] Glowa JR，Fantegrossi WE，Lewis DB，et al.Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate，a long-acting ester derivative of GBR 12909[J].J Med Chem，1996，39：4689-4691.

　　[13] Volkow ND，Ding YS，Fowler JS，et al.Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain[J].Arch Gen Psychiatry，1995，52：456-463.

　　[14] Oldendorf WH.Some relationships between addiction and drug delivery to the brain[J].NIDA Res Monogr，1992，120：13-25.

　　[15] Carroll FI，Howard JL，Howell LL，et al.Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse[J].AAPS J，2006，8：E196-203.

　　[16] Howell LL，Wilcox KM.Functional imaging and neurochemical correlates of stimulant self-administration in primates[J].Psychopharmacology，2002，163：352-361.

　　[17] Newman AH，Kulkarni S.Probes for the dopamine transporter：new leads toward a cocaine-abuse therapeutic-A focus on analogues of benztropine and rimcazole[J].Med Res Rev，2002，22：429-464.

　　[18] Platt DM，Rowlett JK，Spealman RD.Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development[J].Psychopharmacology，2002，163：265-282.

　　[19] O'Brien CP.A range of research-based pharmacotherapies for addiction[J].Science，1997，278：66-70.

　　[20] Rothman RB，Glowa JR.A review of the effects of dopaminergic agents on humans，animals，and drug-seeking behavior，and its implications for medication development.Focus on GBR 12909[J].Mol Neurobiol，1995，11：1-19.

　　[21] Di Chiara G.The role of dopamine in drug abuse viewed from the perspective of its role in motivation[J].Drug Alcohol Depend，1995，38：95-137.

　　[22] Wise RA.Neurobiology of addiction[J].Curr Opin Neurobiol，1996，6：243-251.